Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (CMPS)
NASDAQ:CMPS
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.42Last Year’s EPS
-0.56Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 20.86%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call showcased several positive developments including the completion of dosing in a key trial, strong financial standing, strategic collaborations, and promising long-term data. However, concerns over suicidality and challenges related to trial variability and placebo effects were noted, which are significant but not overwhelming.Company Guidance
During the COMPASS Pathways First Quarter 2025 Earnings Call, key guidance was provided regarding their pivotal Phase III trials for COMP360 in treatment-resistant depression (TRD). The company announced the completion of dosing in Part A of their 005 trial, with top-line results expected in late June, focusing on the difference in change from baseline on the MADRS scale, associated p-value, and confidence interval. Enrollment for the second Phase III trial, COMP006, is progressing well, targeting 26-week results in the second half of 2026. The call also highlighted successful financial positioning, with cash and equivalents at $260 million, sufficient to fund operations through the COMP006 readout. Additionally, strategic collaborations, including a new partnership with HealthPort, aim to enhance access to innovative mental health treatments, potentially including COMP360, if FDA approved.Completion of Dosing in Phase 3 Trial
COMPASS Pathways announced the completion of dosing for all participants in Part A of their pivotal Phase III trial for treating resistant depression (TRD), marking an important milestone.
Strong Financial Position
The company reported cash and cash equivalents of $260 million at the end of March, up from $165 million at the end of 2024, expected to fund operations through Phase 3 trial COMP006 data readout in 2026.
Strategic Collaboration with HealthPort
COMPASS Pathways announced a strategic collaboration with HealthPort, a community health center focused on equitable access to mental health treatments, highlighting the company’s focus on underserved populations.
Positive Long-term Data from Phase 2b Trial
52-week follow-up data from the Phase 2b trial showed that a single 25 mg dose of COMP360 offered long-term benefits, with an average time to depressive event of over 12 weeks.
CMPS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CMPS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $3.74 | $3.76 | +0.53% |
Feb 27, 2025 | $3.70 | $3.92 | +5.95% |
Oct 31, 2024 | $6.19 | $4.76 | -23.10% |
Aug 01, 2024 | $7.63 | $6.88 | -9.83% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does COMPASS Pathways (CMPS) report earnings?
COMPASS Pathways (CMPS) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is COMPASS Pathways (CMPS) earnings time?
COMPASS Pathways (CMPS) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CMPS EPS forecast?
CMPS EPS forecast for the fiscal quarter 2025 (Q2) is -0.42.